Press Releases

Press Releases

or

December 5, 2018
CAMBRIDGE, Mass. and BEIJING, China , Dec. 05, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today
November 27, 2018
BeiGene acquires exclusive development and commercial rights to Zymeworks’ bispecific candidates, ZW25 and ZW49, in Asia (excluding Japan ), Australia, and New Zealand . The companies will collaborate on joint global development for selected indications.
November 20, 2018
CAMBRIDGE, Mass. , and BEIJING, China , Nov. 20, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today